AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.10) per share from the same period last year.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 10:57 AM
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
November 12, 11:58 AM
AcelRx Pharmaceuticals (NASDAQ:ACRX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts estimate that AcelRx Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-0.07
October 4, 12:05 PM
AcelRx Pharmaceuticals (NASDAQ:ACRX) brought in sales totaling $443.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.55%, resulting in a loss of $10.02 million.
AcelRx To Present On Effect Of Administration Of Sufentanil Sublingual Tablet On Reducing Post-Operative Recovery Time And Opioid Use In Plastic Surgery At The Annual Miami Cosmetic Surgery Event Aug. 27
August 26, 8:32 AM
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today